Nuclear Medicine: Page 8

Clarity reaches 50% recruitment for SABRE trial

By AuntMinnie.com staff writers

Radiopharmaceutical developer Clarity Pharmaceuticals has reached 50% recruitment for its Phase II Copper-64 SAR-Bombesin in Biochemical REcurrence of Prostate Cancer (SABRE) trial.

July 23, 2023

SNMMI launches AI challenge

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has launched a radiomics and machine-learning challenge, with the winner to receive a cash prize and certificate.

July 20, 2023

Ratio Therapeutics highlights first patient treated in FAPI PET trial

By AuntMinnie.com staff writers

Ratio Therapeutics, in collaboration with Lantheus and PharmaLogic, has dosed the first patient in a phase I study investigating a novel fibroblast activated protein inhibitor (FAPI)-targeted radiopharmaceutical for PET imaging.

July 19, 2023

PET/CT scans predict outcomes in patients with thyroid cancer

By Will Morton

PET/CT scans in patients with advanced thyroid cancer can predict their response to lenvatinib just one week after they begin treatment -- much faster than contrast-enhanced CT (CECT) exams, according to researchers in Japan.

July 18, 2023

DOE Isotope Program adds manganese-54 to catalog

By AuntMinnie.com staff writers

The U.S. Department of Energy Isotope Program (DOE IP) has added manganese-54 (Mn-54) to its product catalog.

July 18, 2023

New scheme proposed for diagnosing Alzheimer's disease

By Will Morton

Experts have drafted new diagnostic criteria for Alzheimer's disease to reflect recent advances in the field, according to a July 16 presentation delivered at an international conference.

July 17, 2023

Canada grapples with shortage of SPECT agent

By Will Morton

Due to production delays, Canada is facing a shortage of dypyridamole -- an agent used in SPECT myocardial perfusion imaging (MPI) to diagnose coronary artery disease.

July 17, 2023

How should patients manage Lu-PSMA-617 waste disposal?

By Will Morton

A medical physicist in Iowa has crunched the numbers and determined the safest approach for prostate cancer patients receiving Lu-PSMA-617 (Pluvicto) to dispose of their radioactive urine, according to a recent communication in the Journal of Nuclear Medicine.

July 16, 2023

Is PSMA PET/CT cost-effective for primary staging?

By Will Morton

PET/CT scans in patients with prostate cancer may increase costs in Europe and the U.S., yet these costs may be reasonably low compared to the potential expenses of an inaccurate diagnosis, according to a recent study.

July 13, 2023

Pluvicto patient response criteria validated

By Will Morton

Doctors now have a reliable approach for determining whether prostate cancer patients are responding to prostate cancer treatment with Pluvicto, according to research published July 11 in Radiology.

July 11, 2023

SNMMI calls for clarity over Leqembi PET scans

By AuntMinnie.com staff writers

The Society of Nuclear Medicine and Molecular Imagine (SNMMI) has called for clarity over whether amyloid PET scans will be covered for potential candidates for the new Alzheimer's disease drug Leqembi (lecanemab).

July 10, 2023

FDA grants full approval to Alzheimer's disease drug Leqembi

By AuntMinnie.com staff writers

The U.S. Food and Drug Administration (FDA) has granted full approval for Eisai and Biogen's Alzheimer's disease drug Leqembi (lecanemab).

July 6, 2023

Previous Page

Page 8 of 439

Next Page